ArticlePloS one2026
Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study was to investigate the mechanism of action of SB on TRP-induced abnormalities of bone metabolism in LNCaP cells.
methodsThe effects of different concentrations of SB and TRP alone and in combination on the proliferation of LNCaP cells were examined by CCK-8 assay, and the half maximal inhibitory concentration were screened for the subsequent experiments. Transwell migration and invasion assays were used to further investigate the effects of SB and TRP alone and in combination on the migration and invasion ability of LNCaP cells. Based on Tandem Mass Tag (TMT) labeling and liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology, the differentially expressed proteins (DEPs) of LNCaP cells in the control group, SB group, TRP group and combination group were quantified. Bioinformatics technology was used to analyze the DEPs of LNCaP cells in each group. At last, the achieved key targets were verified by western blot.
resultsThe inhibitory effects of different concentrations of SB and TRP alone and in combination on the proliferation, migration and invasion of LNCaP cells showed both time-dependent and concentration-dependent effects, and the inhibitory effects of the combination of drugs on LNCaP cells were more significant. The proteomics results showed that a total of 153 DEPs were identified in the SB group and the control group, 100 DEPs were identified in the TRP group and the control group, and 524 DEPs were identified in the combination group and the control group. Bioinformatics analysis showed that a higher number of DEPs were enriched in the IL-17 signaling pathway in the SB and combined treatment groups compared to the control group. These findings suggest a potential role of SB and the combined treatment in modulating the IL-17 signaling pathway. In contrast, the same DEPs were found to be enriched in both the Circadian entrainment and Apelin signaling pathways in the TRP versus control and combined treatment versus control comparisons.
conclusionsSB may regulate TRP-induced bone metabolism abnormalities in LNCaP cells through the IL-17 signaling pathway as well as five DEPs: p-ERK2, RELA, HSP90B1, GNAI1and GNAI3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.